



ZEALAND PHARMA

CHI clinical trials 2020 update

Delivering on our commitment to patients

Forward-looking statements

This presentation contains information pertaining to Zealand Pharma A/S ("Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or any other information transmitted or made available to the viewer or recipient hereof, whether communicated in written or oral form.

This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire Zealand securities, in any jurisdiction, or an inducement to enter into investment activity, nor shall there be any sale of Zealand securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This presentation contains forward-looking statements that reflect management's current views with respect to Zealand's product candidates' development, clinical and regulatory timelines and anticipated results, market opportunity, potential financial performance and other statements of future events or conditions. Although Zealand believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors, many of which are beyond Zealand's control. No reliance should be made on such forward-looking statements.

Zealand does not intend to update the presentation, including the forward-looking statements contained therein, following distribution, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that lead to changes compared to the date when these statements were provided.

We are pursuing multiple opportunities to improve patients' lives with dasiglucagon via different product modalities

Dasiglucagon

Novel stable glucagon analog

Fast onset-of-action

Unique stability in liquid formulation

Suitable for multiple indications



HypoPal®
rescue pen
for severe
hypoglycemia

NDA filed



Infusion
pump therapy
for recurrent
low blood glucose
in congenital
hyperinsulinism

Phase 3 ongoing



Dual hormone
artificial pancreas
for automated
diabetes management

Phase 3 ready



Mini doses
to correct post-
bariatric surgery
hypoglycemia

Phase 2 results¹

The dasiglucagon development program for children with CHI both pre- and post-diagnosis

Pre-diagnosis

Glucose level stabilization and diagnostic workup

Dasiglucagon infusion for short-term glycemic stabilization

- Short term therapy for focal and diffuse CHI patients
- Replacement of diazoxide or glucagon i.v. infusion¹
- Opportunity to discharge to home

Post-diagnosis


Medical management and/or partial to near-total pancreatectomy

Dasiglucagon infusion for long-term treatment

- Long-term stable euglycemia of diffuse CHI patients
- Elimination or reduction of medical treatment²
- Reduced need for pancreatectomy
- Reduced risk of post-surgical type 1 diabetes

Dasiglucagon as long-term treatment for newborns and children with congenital hyperinsulinism

We aspire to transform the lives of children with CHI



For illustration only

Providing a non-surgical treatment option

Liquid formulation, stable at room and body temperature

All three Phase 3 trials ongoing

EU and U.S. orphan drug designation granted

Clinical trials

ZP 4207-17109

Dasiglucagon in older children with CHI, that have 3 or more hypoglycemias a weeks despite maximum treatment

ZP 4207-17103

Dasiglucagon in newborn children and young infants with newly diagnosed CHI

ZP 4207-17103

Safety extension to run-in trials for children who need long term dasiglucagon therapy

